143 related articles for article (PubMed ID: 15361768)
1. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling.
Pagnin E; Davis PA; Sartori M; Semplicini A; Pessina AC; Calò LA
J Hypertens; 2004 Oct; 22(10):1963-9. PubMed ID: 15361768
[TBL] [Abstract][Full Text] [Related]
2. Reduced mRNA and protein content of rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension.
Pagnin E; Semplicini A; Sartori M; Pessina AC; Calò LA
Am J Hypertens; 2005 Sep; 18(9 Pt 1):1200-5. PubMed ID: 16182110
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension.
Calò LA; Pagnin E; Davis PA; Sartori M; Ceolotto G; Pessina AC; Semplicini A
J Clin Endocrinol Metab; 2004 Aug; 89(8):4153-7. PubMed ID: 15292363
[TBL] [Abstract][Full Text] [Related]
4. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes.
Calò LA; Pagnin E; Ceolotto G; Davis PA; Schiavo S; Papparella I; Semplicini A; Pessina AC
J Hypertens; 2008 May; 26(5):938-45. PubMed ID: 18398336
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling.
Calò LA; Pagnin E; Davis PA; Sartori M; Semplicini A
Nephrol Dial Transplant; 2003 Aug; 18(8):1518-25. PubMed ID: 12897089
[TBL] [Abstract][Full Text] [Related]
6. Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients.
Calò LA; Davis PA; Pagnin E; Dal Maso L; Maiolino G; Seccia TM; Pessina AC; Rossi GP
J Hypertens; 2014 Feb; 32(2):331-8. PubMed ID: 24356540
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension.
Calò LA; Schiavo S; Davis PA; Pagnin E; Mormino P; D'Angelo A; Pessina AC
J Hypertens; 2010 Jan; 28(1):111-8. PubMed ID: 19797979
[TBL] [Abstract][Full Text] [Related]
8. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?
Calò LA; Montisci R; Scognamiglio R; Davis PA; Pagnin E; Schiavo S; Mormino P; Semplicini A; Palatini P; D'Angelo A; Pessina AC
J Endocrinol Invest; 2009 Nov; 32(10):832-6. PubMed ID: 19605975
[TBL] [Abstract][Full Text] [Related]
9. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways.
Calò LA; Puato M; Schiavo S; Zanardo M; Tirrito C; Pagnin E; Balbi G; Davis PA; Palatini P; Pauletto P
Nephrol Dial Transplant; 2008 Sep; 23(9):2804-9. PubMed ID: 18344243
[TBL] [Abstract][Full Text] [Related]
10. Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter's and Gitelman's syndromes, human models of endogenous angiotensin II signaling antagonism.
Calò LA; Davis PA; Rossi GP
J Hypertens; 2014 Nov; 32(11):2109-19; discussion 2119. PubMed ID: 25202962
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
Kobayashi N; Nakano S; Mita S; Kobayashi T; Honda T; Tsubokou Y; Matsuoka H
J Pharmacol Exp Ther; 2002 May; 301(2):459-66. PubMed ID: 11961044
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.
Calò LA; Maiolino G
J Endocrinol Invest; 2015 Jul; 38(7):711-6. PubMed ID: 25740064
[TBL] [Abstract][Full Text] [Related]
13. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression.
Takeda K; Ichiki T; Tokunou T; Iino N; Fujii S; Kitabatake A; Shimokawa H; Takeshita A
Arterioscler Thromb Vasc Biol; 2001 May; 21(5):868-73. PubMed ID: 11348889
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension.
Ravarotto V; Pagnin E; Fragasso A; Maiolino G; Calò LA
High Blood Press Cardiovasc Prev; 2015 Sep; 22(3):215-23. PubMed ID: 25759028
[TBL] [Abstract][Full Text] [Related]
15. Early markers of inflammation in a high angiotensin II state--results of studies in Bartter's/Gitelman's syndromes.
Davis PA; Mussap M; Pagnin E; Bertipaglia L; Savica V; Semplicini A; Calò LA
Nephrol Dial Transplant; 2006 Jun; 21(6):1697-701. PubMed ID: 16574683
[TBL] [Abstract][Full Text] [Related]
16. Insulin signaling, glucose metabolism, and the angiotensin II signaling system: studies in Bartter's/Gitelman's syndromes.
Davis PA; Pagnin E; Semplicini A; Avogaro A; Calò LA
Diabetes Care; 2006 Feb; 29(2):469-71. PubMed ID: 16443917
[No Abstract] [Full Text] [Related]
17. Gitelman's and Bartter's Syndromes: From Genetics to the Molecular Basis of Hypertension and More.
Ravarotto V; Bertoldi G; Stefanelli LF; Nalesso F; Calò LA
Kidney Blood Press Res; 2022; 47(9):556-564. PubMed ID: 35858584
[TBL] [Abstract][Full Text] [Related]
18. Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling.
Calò LA; Facco M; Davis PA; Pagnin E; Maso LD; Puato M; Caielli P; Agostini C; Pessina AC
Hypertens Res; 2011 Sep; 34(9):1017-22. PubMed ID: 21654754
[TBL] [Abstract][Full Text] [Related]
19. Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype?
Calò LA; Davis PA
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784543
[TBL] [Abstract][Full Text] [Related]
20. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications.
Calò LA; Schiavo S; Davis PA; Pagnin E; Mormino P; D'Angelo A; Pessina AC
J Nephrol; 2010; 23(4):472-7. PubMed ID: 20349406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
